Published within
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
A phase III trial of Roche's Xelox regimen in colorectal cancer has proven successful, with the study finding Xelox to be as effective as FOLFOX, the current standard first-line treatment for metastatic colorectal tumors. However, numerous challenges still face Roche if the regimen is to make a significant impact upon the colorectal tumor market.
Published By Datamonitor
|
02 Aug 2006 |
|
CommentWire
|
Preliminary results show the combination of Xeloda plus Eloxatin, known as XELOX, to be equivalent to standard FOLFOX-4 chemotherapy treatment in terms of overall survival in first-line metastatic colorectal cancer patients. Given its dosing convenience advantage, XELOX has the potential to be a first-line treatment, provided it can be demonstrated as cost-effective.
Published By Datamonitor
|
23 Jan 2007 |
|
CommentWire
|
Like many drugs, and some foods, Xeloda interacts negatively with popular anticoagulant warfarin. This may reduce the use of Xeloda in cancer patients requiring anticoagulation. It also highlights the potential of AstraZeneca's new oral anticoagulant, ximelagatran, which is currently undergoing phase III trials and is not associated with the interactions that plague warfarin.
Published By Datamonitor
|
07 Nov 2001 |
|
CommentWire
|
Researchers have found that Roche's [ROCZ.S] anemia treatment NeoRecormon might worsen survival in head and neck cancer patients who undergo radiotherapy. Despite the poor findings, the study is unlikely to have any significant repercussions for NeoRecormon's rival erythropoietins, Amgen's [AMGN] Epogen and J&J's [JNJ] Procrit.
Published By Datamonitor
|
20 Oct 2003 |
|
CommentWire
|
Roche has agreed to acquire Piramed for $160m plus a milestone payment of $15m, due upon the start of Phase II clinical trials for the company's oncology program. Piramed's oncology and immunology and inflammation programs will add to Roche's already strong portfolio in these therapy areas and the move is in line with Roche's strategy of pursuing these two fastest growing therapeutic segments.
Published By Datamonitor
|
15 Apr 2008 |
|
CommentWire
|
A phase III clinical trial of Roche's [ROCZg.VX] MabThera (rituximab) in patients below 60 years of age with aggressive non-Hodgkin's lymphoma was halted early because its primary efficacy endpoint was met two years earlier than expected. These trial results are likely to consolidate MabThera's position as the best-selling innovative agent for cancer.
Published By Datamonitor
|
08 Dec 2003 |
|
CommentWire
|
Roche has announced that it will acquire GlycArt for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology, markets. The deal promises to strengthen Roche's drug development capabilities and help maintain the large increases in sales drawn from its therapeutic anti-cancer antibodies.
Published By Datamonitor
|
20 Jul 2005 |
|
CommentWire
|
Scientists have found that HER-2 is a key contributor to the development of pre-invasive breast cancer. Roche/Genentech's Herceptin, currently used to treat advanced breast cancer, can target HER-2. However, the detection of elevated HER-2 is not routine among most physicians. Despite this, Herceptin is well positioned to build its usage in early-stage and pre-cancerous populations.
Published By Datamonitor
|
14 Apr 2003 |
|
CommentWire
|
Following the approval of Bristol-Myers Squibb's Sprycel in the US in June 2006 and EU in November 2006, Novartis has completed regulatory submissions for Gleevec follow-up Tasigna with both the FDA and EMEA. Despite Sprycel's first-to-market status, Novartis is well placed in the CML market via its experience with Gleevec to meet this challenge.
Published By Datamonitor
|
28 Nov 2006 |
|
CommentWire
|
Patients with chronic myeloid leukemia (CML) receiving 800mg of Glivec are more likely to attain complete cytogenetic response compared to the standard dose of 400mg. If these preliminary results translate into improved survival for CML patients then this will undoubtedly secure further revenue for Novartis [NVS] as physicians switch to high dose Glivec.
Published By Datamonitor
|
07 Dec 2004 |
|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.